To ensure the generalizability of clinical trial results and equitable treatment access, enrollment must reflect the diversity of the patient population.
Vol.26/No.10
Heather McArthur, MD, MPH, FASCO, elaborates on clinical trial data for palazestrant monotherapy in breast cancers.
Balazs Halmos, MD, MS, and Jamie E. Chaft, MD, discuss how safety considerations contribute to treatment selection in NSCLC.
Maurie Markman, MD, discusses the role of decision support tools in cancer management.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5